Pfizer Says COVID-19 Vaccine Will Value $110-$130 Per Dose

By TOM MURPHY, AP Health Writer

Pfizer will cost $110 to $130 for a dose of its COVID-19 vaccine as soon as the U.S. authorities stops shopping for the pictures, however the drugmaker says it expects many individuals will proceed receiving it free of charge.

Pfizer executives mentioned the business pricing for grownup doses may begin early subsequent 12 months, relying on when the federal government phases out its program of shopping for and distributing the pictures.

The drugmaker mentioned it expects that individuals with non-public medical insurance or protection via public applications like Medicare or Medicaid can pay nothing. The Affordable Care Act requires insurers to cowl many really helpful vaccines with out charging any out-of-pocket bills.

A spokesman mentioned the corporate additionally has an income-based help program that helps eligible U.S. residents with no insurance coverage get the pictures.

Political Cartoons

The worth would make the two-dose vaccine dearer for cash-paying prospects than annual flu pictures. Those can vary in worth from round $50 to $95, relying on the kind, in response to CVS Health, which runs one of many nation’s greatest drugstore chains.

A Pfizer govt mentioned Thursday that the value displays elevated prices for switching to single-dose vials and business distribution. The govt, Angela Lukin, mentioned the value was nicely under the thresholds “for what can be thought of a extremely efficient vaccine.”

The drugmaker mentioned final 12 months that it was charging the U.S. $19.50 per dose, and that it had three tiers of pricing globally, relying on every nation’s monetary scenario. In June, the corporate mentioned the U.S. authorities would purchase a further 105 million doses in a deal that amounted to roughly $30 per shot. The authorities has the choice to buy extra doses after that.

Pfizer’s two-shot vaccine debuted in late 2020 and has been the most typical preventive shot used to battle COVID-19 within the U.S.

More than 375 million doses of the unique vaccine, which Pfizer developed with the German drugmaker BioNTech, have been distributed within the U.S., in response to the Centers for Disease Control and Prevention.

That doesn’t rely one other 12 million doses of an up to date booster that was accepted earlier this 12 months.

The vaccine introduced in $36.78 billion in income final 12 months for Pfizer and was the drugmaker’s top-selling product.

Analysts predict that it’ll rack up one other $32 billion this 12 months, in response to FactSet. But additionally they anticipate gross sales to fall quickly after that.

More than 90% of the grownup U.S. inhabitants has already acquired at the very least one dose of COVID-19 vaccine, in response to the CDC. But solely about half that inhabitants has additionally acquired a booster dose.

The Associated Press Health and Science Department receives help from the Howard Hughes Medical Institute’s Department of Science Education. The AP is solely liable for all content material.